Myeloma2018 Session IV

 

Novel Targets

The central theme for session IV at the Myeloma2018 meeting was novel drug targets for MM targets. Nizar Bahlis, MD, and Enrique Ocio, MD, PhD, identify MCL-1 as a possible target in MM, indicating a potential niche for MCL-1 inhibitors. Leif Bergsagel, MD, Robert Orlowski, MD, PhD, and Keith Stewart, MBChB, explore further drug targets.

Presentations
Targeting Ectopic Enhancer-driven Oncogene Dysregulation in Multiple Myeloma
Leif Bergsagel, MD, PhD
Mayo Clinic, Phoenix, AZ
8 September, 2018

Leif Bergsagel, MD, PhD, from the Mayo Clinic, Phoenix, AZ, discusses targeting cctopic enhancer-driven oncogene dysregulation in multiple myeloma.

PROTACs Targeting BRD4
Robert Orlowski, MD
MD Anderson Cancer Center, Houston, TX
8 September, 2018

Robert Orlowski, MD, from the MD Anderson Cancer Center, Houston, TX, speaks about PROTACs targeting BRD4.

PIKfyve in Myeloma
Keith Stewart, MBChB
Mayo Clinic, Rochester, MN
8 September, 2018

Keith Stewart, MBChB, from the Mayo Clinic, Rochester, MN, discusses PIKfyve in myeloma.

Simultaneous Targeting of MCL-1 and BCL-2 in Multiple Myeloma
Enrique Ocio, MD, PhD
University Hospital of Salamanca, Salamanca, Spain
8 September, 2018

Enrique Ocio, MD, PhD, from the University Hospital of Salamanca, Salamanca, talks about MCL-1 and BCL-2 inhibitors.

PROTAC-Mediated Degradation of MCL-1
Nizar Bahlis, MD
University of Calgary, Calgary, Canada
8 September, 2018

Nizar Bahlis, MD, from the University of Calgary, Calgary, Canada, discusses PROTAC-mediated degradation of MCL-1.